Compounds for the treatment of paramyxovirus viral infections
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
1. A compound of Formula (II), or a pharmaceutically acceptable salt thereof, having the structure:
A b -L b -Y b (II)
wherein:
L b is
A b is phenyl, wherein the phenyl is unsubstituted or substituted with one or more groups selected from the group consisting of:
(a) hydroxy,
(b) halogen,
(c) nitro,
(d) alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, and —O(C 1-6 alkyl),
(e) amino optionally substituted with one or two alkyl groups,
(f) —O-(alkyl) optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, alkoxy, cyano, amino optionally substituted with one or two alkyl groups, cycloalkyl, C-carboxy, and C-amido, and
(g) —O-(cycloalkyl) optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, alkyl, alkoxy, and amino optionally substituted with one or two alkyl groups;
Y b is benzothiophenyl optionally substituted with one or more groups selected from the group consisting of halogen, alkyl optionally substituted with one or more halogen groups, hydroxy, alkenyl, alkynyl, alkoxy optionally substituted with one or more halogen groups, haloalkoxy, cyano, C-carboxy, —C-amido, sulfonyl, and aryl;
R 1b is hydrogen or an unsubstituted C 1-4 alkyl;
R 2b and R 2b1 are each independently hydrogen or C 1-4 alkyl optionally substituted with one or more groups selected from the group consisting of hydroxy, alkoxy, amino, and C-carboxy, and when more than one R 2b and/or more than one R 2b1 are present, each R 2b and each R 2b1 is the same or different; and
ring B1 is pyridinyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogen, hydroxy, alkenyl, alkynyl, cycloalkyl, aryl, alkoxy optionally substituted with one or more halogen groups, amino optionally substituted with one or more alkyl groups, C-carboxy, and alkyl optionally substituted with one or more groups selected from hydroxy, alkoxy, halo, and cycloalkyl.
2. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.
3. The pharmaceutical composition of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt of any of the foregoing.
4. The compound of claim 1 , wherein B1 is selected from the group consisting of: an optionally substituted
an optionally substituted
and an optionally substituted
5. The compound of claim 1 , wherein R 1b is hydrogen.
6. The compound of claim 1 , wherein R 2b and R 2b1 both are hydrogen.
7. The compound of claim 1 , wherein R 2b and R 2b1 both are an optionally substituted C 1-4 alkyl.
8. The compound of claim 1 , wherein A b is a di-substituted phenyl.